- Melanoma risk is not significantly increased with biologic therapy for common inflammatory diseases, according to a systematic review and meta-analysis.
Why this matters
- The authors cite concerns regarding long-term risk for cancer in patients treated with biologic therapy.
- Compared with conventional systemic therapy, biologic treatment was not significantly associated with pooled relative risks (95% CIs) for melanoma in patients with:
- IBD: 1.20 (0.60-2.40).
- Rheumatoid arthritis (RA): 1.20 (0.83-1.74).
- Psoriasis: 1.57 (0.61-4.09).
- Compared with conventional systemic therapy, pooled relative risks (95% CIs) for melanoma were not significantly affected by RA treatment with:
- TNF inhibitor: 1.08 (0.81-1.43).
- Rituximab: 0.73 (0.38-1.39).
- Abatacept: 1.43 (0.66-3.09).
- 7 cohort studies (34,029 patients treated with biologic therapy and 135,370 biologic-naive patients treated with conventional systemic therapy) were included.
- Funding: Psoriasis Association.
- Heterogeneity among included studies.
- Lack of adjustment for related risk factors.